The drug named Cima Vax EGF has shown good results to raise survival rates of four to five months and even longer in some patients on average basis, the scientists stated in a new conference at Cuba’s Center of Molecular Immunology.
Contrary to chemotherapy, Cima Vax EGF has fewer side effects because it contains modified proteins that target only the cancer cells.
The scientists told that there were other vaccines currently being tested in other parts of the world but CimaVax EGF was the first lung cancer approved vaccine anywhere in the world.
Gisela Gonzalez, who led the development of the vaccine that was started in 1992, stated that “It is the first registered lung cancer vaccine in the world that will surely help the patients with cancers to increase survival.”
According to Gonzalez, in many other countries the drug is under different stages of clinical trials and possibly it would be approved in Peru next and available publicly by the end of this year.
The vaccine will be produced in Cuba, however, many other private companies has been licensed to market the vaccine. The cost for treatment has not been decided yet, Gonzalez further added.
“People who live outside Cuba can also come to the island for getting treatment”, said Tania Crombet who is director of clinical investigation at Havana’s molecular immunology center.
Articles published in CoolHealthTips.com are unique and property of the site only. Copying Content or Publishing Article from CoolHealthTips.com is strictly not allowed and against Site’s policy.